Breast cancer and vitamin D in postmenopausal minorities.

2012 ◽  
Vol 30 (27_suppl) ◽  
pp. 17-17
Author(s):  
Demet Gokalp Yasar ◽  
Pam Khosla
Keyword(s):  
Breast Cancer ◽  
Vitamin D ◽  
Vitamin D Deficiency ◽  
Cancer Patients ◽  
Bone Health ◽  
Postmenopausal Breast Cancer ◽  
Cancer Information ◽  
Minority Population ◽  
Breast Cancer Patients ◽  
Significant Difference

17 Background: Bone health is a particular concern for breast cancer survivors, because these women have 15% higher fracture risk than women without a history of breast cancer. Many studies have suggested that vitamin D deficiency may be involved in breast cancer initiation, progression, and prognosis. This study examines the prevalence of vitamin D deficiency among postmenopausal breast cancer patients in minority population. Methods: This retrospective study reviewed the electronic records of 200 postmenopausal breast cancer patients from ethnic groups of blacks, Hispanics and Asians. Results: Of the 200 patients, 84 (42%) had their 25-OHD levels checked at least once. Of patients, 42.7% found body mass index (BMI)>30kg/m2. There was significant difference between race and BMI (p<0.05). Black Vitamin D deficiency (level< 20ng/mL) found in 35 (41.7%), vitamin D insufficiency (level range 20-30ng/mL) found in 30 (35.7%) of the patients. The median serum 25-OHD level was 21 (range 4-65ng/ml). The serum 25-OHD levels did not have significant difference among blacks and Hispanics. Tumor stages found negatively correlated with 25-OHD levels r=-0.227 and p=0.04. Conclusions: This study revealed that vitamin D deficiency has a high prevalence among postmenopausal breast cancer minority population. Data from Third National Health and Nutrition Examination survey showed that mean serum 25-OHD levels among white, Hispanic and black women were 76ng/ml, 56.7ng/ml and 45.3ng/ml, respectively. Also, prevalence rate of vitamin D deficiency is reported in the studies among breast cancer patients are approximately 30%. Our data compared with this general population’s numbers is low; our median 25-OHD level was 21ng/ml. Our study found negative correlation with Vitamin D levels and stages of the breast cancer. Information is lacking on direct prognostic effect of vitamin D in breast cancer but this findings including our study support the hypothesis that vitamin D has a role in the pathogenesis of breast cancer. In the setting of breast cancer diagnosis either for bone health, or for breast cancer prognosis in postmenopausal women, we advocate routine 25-OHD levels screening for the vitamin D deficiency especially in minority populations would be beneficial.

High prevalence of vitamin D deficiency in a multi-ethnic cohort of premenopausal breast cancer patients

2008 ◽  
Vol 26 (15_suppl) ◽  
pp. 9583-9583 ◽  
Author(s):  
K. D. Crew ◽  
E. Shane ◽  
S. Cremers ◽  
D. J. McMahon ◽  
D. Irani ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Vitamin D ◽  
Vitamin D Deficiency ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Premenopausal Breast Cancer ◽  
High Prevalence

scholarly journals Evaluation of Pentosidine as Bone Quality Marker in Postmenopausal Breast Cancer Patients Receiving Aromatase Inhibitors

2020 ◽  
Author(s):  
Hideo Shigematsu ◽  
Tomoyuki Yoshiyama ◽  
Daisuke Yasui ◽  
Shinji Ozaki
Keyword(s):  
Breast Cancer ◽  
Bone Turnover ◽  
Cancer Patients ◽  
Bone Quality ◽  
Bone Turnover Markers ◽  
Postmenopausal Breast Cancer ◽  
Breast Cancer Patients ◽  
Significant Difference ◽  
Average Change ◽  
Turnover Markers

Abstract Background: Osteoporosis and fractures are important aromatase inhibitor (AI) related adverse events in postmenopausal women with hormone receptor positive breast cancer. An increment of pentosidine is associated with a deterioration of bone quality. In this study, pentosidine was evaluated in postmenopausal breast cancer patients receiving AIs. Methods: Fifty postmenopausal breast cancer patients receiving AIs were retrospectively evaluated. Sixteen patients were given a bone modifying agent (BMA) concomitant with AIs. Changes of pentosidine, bone turnover markers and bone mineral density (BMD) before and after 12 months of AI therapy were compared between BMA administered patients (BMA group) and a non-BMA group.Results: There was no significant difference between pentosidine low and high groups in regard to age, height, weight, BMD of femoral neck and lumbar spine, and bone turnover markers including TRACP-5b and BAP. In the non-BMA group, pentosidine was increased in 18 cases (53%), and the average change of pentosidine was 21.5% (95%CI; 0.23 to 42.7%, p=0.048). In the BMA group, pentosidine was increased in 2 two cases (13%), and the average change of pentosidine was -16.6% (95%CI; -30.6 to -2.6%, p=0.023). There was a significantly lower proportion of pentosidine-increased cases (p=0.0065) and decrease of pentosidine (p=0.021) in the BMA group compared to those in the non-BMA group. Conclusions: Pentosidine was an independent factor from risk factors of osteoporotic fracture. Pentosidine was increased with AI, however, BMA inhibits an AI-induced increase of pentosidine in postmenopausal breast cancer patients.

Evaluation of Vitamin D Deficiency in Breast Cancer Patients on Bisphosphonates

2008 ◽  
Vol 13 (7) ◽  
pp. 821-827 ◽  
Author(s):  
Andrea Wang‐Gillam ◽  
Dorothy A. Miles ◽  
Laura F. Hutchins
Keyword(s):  
Breast Cancer ◽  
Vitamin D ◽  
Vitamin D Deficiency ◽  
Cancer Patients ◽  
Breast Cancer Patients

Weight gain in breast cancer patients: Tamoxifen versus anastrazole

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 10544-10544
Author(s):  
P. McGowan ◽  
M. C. Perry ◽  
J. E. Hewett ◽  
B. Ge ◽  
K. Sanfilippo
Keyword(s):  
Breast Cancer ◽  
Weight Gain ◽  
Hormone Therapy ◽  
Cancer Patients ◽  
Postmenopausal Breast Cancer ◽  
Breast Cancer Patients ◽  
Significant Weight Gain ◽  
Estrogen Receptor Modulators ◽  
Significant Difference ◽  
Group A

10544 Background: Weight gain is a common complaint among breast cancer patients, especially those taking tamoxifen. Aromatase inhibitors have been increasingly used in postmenopausal breast cancer patients, and are generally thought to have a more tolerable side-effect profile than selective estrogen receptor modulators (SERM’s). This study specifically addresses weight gain in patients on the SERM, tamoxifen, compared to patients on the aromatase inhibitor, anastrazole. Methods: Ninety-six outpatients with primary breast cancer of any stage received standard doses of adjuvant hormonal therapy. Seventy received tamoxifen (Group T) and 26 anastrazole (Group A). The nursing staff in the clinic weighed all patients at the time of diagnosis, at start of chemotherapy (if received), at start of hormone therapy, and at 3 month intervals for 12 months after starting hormone therapy. Data were gathered in a retrospective manner. Results: Demographic variables were compared between the two groups. In all patients, it was noted that increasing age was correlated with greater weight gain at 3 months after starting hormone therapy (p = 0.0257), but not at any other intervals. No other variables were significantly correlated with weight gain. In Group T, mean weight gain was clinically (>1.8 kgs) and statistically significant at 9 and 12 months (p = 0.0137, p = 0.0003). In Group A, mean weight gain was not clinically significant at any point. Using the Wilcoxon two-sample tests to compare groups T and A, it was shown that there was no statistically significant difference in weight gain between the two groups at any interval (see table). Conclusions: These results are consistent with previous studies that show significant weight gain in breast cancer patients on tamoxifen. This study failed to show a statistically significant difference in weight gain between patients on tamoxifen and patients on anastrazole. Group A did not have statistically significant weight gain at any interval after starting hormone therapy. [Table: see text] No significant financial relationships to disclose.

Is vitamin D deficiency in breast cancer patients associated with aggressive prognosis?

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. e12511-e12511
Author(s):  
Omalkhair A. M. Abulkhair ◽  
Ahmed Gasmelseed ◽  
Ola Makram ◽  
Ahmed Saadeddin ◽  
Ahmed Hashim Mohamed
Keyword(s):  
Breast Cancer ◽  
Vitamin D ◽  
Vitamin D Deficiency ◽  
Cancer Patients ◽  
Breast Cancer Patients

scholarly journals Vitamin D Deficiency and Tumor Response Failure in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy at a Medical Center in Mexico

2021 ◽  
pp. 1-4
Author(s):  
Salvador Macias-Diaz ◽  
Salvador Macias-Diaz ◽  
Ana Lilia Castruita Avila ◽  
Joaquin Gabriel Reinoso Toledo ◽  
Mario Garcia Carrasco
Keyword(s):  
Breast Cancer ◽  
Vitamin D ◽  
Neoadjuvant Chemotherapy ◽  
Vitamin D Deficiency ◽  
Cancer Patients ◽  
Tumor Response ◽  
Clinical Stage ◽  
Molecular Profile ◽  
P Value ◽  
Breast Cancer Patients

Background: Vitamin D deficiency has been associated with not achieving a complete pathological response in patients with breast cancer after neoadjuvant chemotherapy. The objective of this study was to determine whether vitamin D deficiency is associated with tumor response failure in patients with breast cancer operated and who received neoadjuvant chemotherapy. Materials and Methods: This was a prospective, cross-sectional, analytical and observational study. Vitamin D was measured in patients with breast cancer who had received neoadjuvant chemotherapy and its association with tumor response was determined. For the inferential analysis, the Student’s t-test, chi-square test, and Fisher’s exact test were used. A p value <0.05 was considered statistically significant. Results: Thirty-six patients were included. There was tumor response failure to treatment in 69.3% and vitamin D deficiency occurred in 58.3%. No association was found between vitamin D deficiency and tumor response failure (p = 0.729), histological type (p = 0.691), molecular profile (p = 0.969), clinical stage (p = 0.468) or menopause status (p = 0.701). Conclusion: Vitamin D deficiency is not associated with tumor response failure in breast cancer patients who received neoadjuvant chemotherapy.

Bone health and adherence to vitamin D and calcium therapy in early breast cancer patients on endocrine therapy with aromatase inhibitors

The Breast ◽  
2017 ◽  
Vol 31 ◽  
pp. 16-19 ◽  
Author(s):  
Lidija Bošković ◽  
Maja Gašparić ◽  
Marija Petković ◽  
Damir Gugić ◽  
Ingrid Belac Lovasić ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Vitamin D ◽  
Cancer Patients ◽  
Endocrine Therapy ◽  
Early Breast Cancer ◽  
Aromatase Inhibitors ◽  
Bone Health ◽  
Breast Cancer Patients

scholarly journals Vitamin D Status and Association of VDR Genetic Polymorphism to Risk of Breast Cancer in Ethiopia

Nutrients ◽  
2019 ◽  
Vol 11 (2) ◽  
pp. 289 ◽  
Author(s):  
Jemal Ahmed ◽  
Eyasu Makonnen ◽  
Alan Fotoohi ◽  
Getnet Yimer ◽  
Daniel Seifu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Vitamin D ◽  
Vitamin D Deficiency ◽  
Cancer Patients ◽  
Treated Group ◽  
Genetic Variations ◽  
Tumor Characteristics ◽  
Breast Cancer Patients ◽  
Severe Vitamin ◽  
Increased Risk

Emerging evidence associates vitamin D deficiency and vitamin D receptor (VDR) genetic variations with risk for breast cancer. This study investigated the prevalence of vitamin D deficiency and its association with tumor characteristics and the implications of VDR genetic variations for risk of breast cancer in Ethiopia. This unmatched case–control study involved 392 female breast cancer patients and 193 controls. The plasma 25-hydroxyvitamin D (25(OH)D3) level was quantified in chemotherapy-naïve (N = 112) and tamoxifen-treated patients (N = 89). Genotyping for the VDR common variant alleles rs7975232 (ApaI), rs2228570 (FokI), and rs731236 (TaqI) was done. Eighty-six percent of the patients were vitamin D deficient (<50 nmol/L). Chemotherapy-naïve breast cancer patients had a higher prevalence of vitamin D deficiency (91.9% vs. 78.3%) compared to the tamoxifen-treated group (p < 0.001). The prevalence of severe vitamin D deficiency (<25 nmol/L) was significantly higher in chemotherapy-naïve (41.1%) than tamoxifen-treated (11.2%) patients. Vitamin D deficiency was not significantly associated with tumor characteristics or VDR genotype. The rs2228570 GG genotype was associated with increased risk of breast cancer (OR = 1.44, 95% confidence interval = 1.01−2.06). Our result indicates that rs2228570 might be a moderate risk factor for breast cancer development in the Ethiopian population. The high prevalence of severe vitamin D deficiency in treatment-naïve breast cancer patients indicates the need for nutritional supplementation of vitamin D at the time of chemotherapy initiation.

Sign in / Sign up

Export Citation Format

Share Document